Friday 6 November 2026
Export ZBH’s income statement to Excel — free account
Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.
- Revenue
- +3.07%
- EPS
- −13.5%
- Free cash flow
- +29.8%
- Total debt
- −7.50%
Quarter to September 2026, against a year earlier
105.28
1.57
−1.47%
Follow ZBH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
25.19 | 23.36 | 20.85 | 22.36 |
P/S ratio |
2.16 | 2.10 | 1.94 | 1.97 | |
P/FCF ratio |
16.53 | 17.49 | 15.96 | 15.16 | |
P/Operating CF |
34.41 | 49.06 | 36.95 | 30.22 | |
P/B ratio |
1.40 | 1.39 | 1.31 | 1.34 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.00 | 2.93 | 2.78 | 2.80 | |
EV/EBITDA |
11.28 | 10.78 | 10.21 | 10.59 | |
EV/Operating CF |
14.57 | 14.75 | 13.55 | 12.75 | |
EV/FCF |
22.96 | 24.48 | 22.78 | 21.53 | |
Quick Ratio |
0.89 | 0.75 | 0.72 | 0.63 | |
Current Ratio |
1.98 | 1.73 | 1.69 | 1.46 | |
Net Debt/EBITDA |
15.80 | 10.96 | 11.84 | 0.00 | |
Debt/Assets |
32.56% | 32.88% | 32.81% | 31.88% | |
Debt/Equity |
0.59 | 0.59 | 0.59 | 0.59 | |
Asset Turnover |
0.37 | 0.37 | 0.37 | 0.36 | |
Operating CF/Net income |
3.71 | 1.51 | 2.26 | 2.92 | |
Capex/Depreciation |
(0.71) | (0.56) | (0.75) | (0.75) | |
Interest Coverage |
2.15 | 5.42 | 4.47 | 4.11 | |
Research and Development Expense of Revenue |
5.29% | 4.96% | 4.81% | 5.13% | |
Selling, General and Administrative Expense of Revenue |
38.87% | 40.73% | 41.31% | 41.45% | |
Intangible Assets out of Total Assets |
0.64 | 0.64 | 0.63 | 0.64 | |
Share Based Compensation of Revenue |
1.07% | 1.16% | 1.13% | 1.17% | |
Graham Net Nets |
(0.30) | (0.29) | (0.31) | (0.34) | |
Graham Number |
71.79 | 75.25 | 78.15 | 0.00 | |
Earnings Yield |
3.97% | 4.28% | 4.80% | 4.47% | |
Free Cash Flow Yield |
6.05% | 5.72% | 6.26% | 6.60% | |
Revenue per Share |
11.33 | 10.70 | 11.33 | 10.83 | |
Operating CF per Share |
2.61 | 1.84 | 2.33 | 2.94 | |
Capex per Share |
(1.02) | (0.78) | (1.05) | (1.12) | |
Free Cash Flow per Share |
1.60 | 1.06 | 1.28 | 1.82 | |
Cash per Share |
2.99 | 2.18 | 2.13 | 2.10 | |
Shareholders Equity per Share |
64.17 | 65.03 | 65.73 | 66.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
64.17 | 65.03 | 65.73 | 66.80 | |
Free Cash Flow |
315.90 | 206.90 | 246.00 | 347.40 | |
Working Capital |
2,536.20 | 2,098.20 | 2,083.20 | 1,626.60 | |
Capital Expenditures |
(201.50) | (152.50) | (201.80) | (212.60) | |
Net Current Asset Value |
(5,266.10) | (5,077.50) | (5,068.60) | (5,684.00) | |
EV/EBIT |
22.52 | 20.93 | 19.60 | 20.69 | |
Capex to Sales |
0.09 | 0.07 | 0.09 | 0.10 | |
Price to Operating Income |
16.21 | 14.96 | 13.73 | 14.57 | |
| Other line items | |||||
Average Receivables |
1,592.55 | 1,631.00 | 1,690.40 | 1,707.15 | |
Average Payables |
248.80 | 331.25 | 350.55 | 336.40 | |
Average Inventory |
2,260.85 | 2,245.50 | 2,362.25 | 2,425.45 | |
Average Assets |
22,228.50 | 22,452.75 | 22,831.45 | 23,513.30 | |
Average Common Equity |
12,591.00 | 12,542.65 | 12,583.45 | 12,745.80 |
Columns are period end dates · fundamentals updated 5 Nov 2026